NATUS MEDICAL INC's gross profit margin for the second quarter of its fiscal year 2015 is essentially unchanged when compared to the same period a year ago. The company has grown its sales and net income during the past quarter when compared with the same quarter a year ago, and although its growth in net income has outpaced the industry average, its revenue growth has not. NATUS MEDICAL INC is extremely liquid. Currently, the Quick Ratio is 2.36 which clearly shows the ability to cover any short-term cash needs. The company managed to increase its liquidity from the same period a year ago, despite already having strong liquidity to begin with. This would indicate improved cash flow.
During the same period, stockholders' equity ("net worth") has increased by 13.12% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q2 FY15||Q2 FY14|
|Net Sales ($mil)||91.94||86.32|
|Net Income ($mil)||9.85||7.46|
|Balance Sheet||Q2 FY15||Q2 FY14|
|Cash & Equiv. ($mil)||73.24||56.02|
|Total Assets ($mil)||453.86||419.71|
|Total Debt ($mil)||0.0||16.41|
|Profitability||Q2 FY15||Q2 FY14|
|Gross Profit Margin||60.08||61.91|
|Return on Assets||8.08||7.05|
|Return on Equity||9.82||8.96|
|Debt||Q2 FY15||Q2 FY14|
|Share Data||Q2 FY15||Q2 FY14|
|Shares outstanding (mil)||32.9||32.27|
|Div / share||0.0||0.0|
|Book value / share||11.36||10.24|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||259545.0||250576.0|
BUY. This stock's P/E ratio indicates a premium compared to an average of 34.06 for the Health Care Equipment & Supplies industry and a significant premium compared to the S&P 500 average of 21.18. Conducting a second comparison, its price-to-book ratio of 4.07 indicates a premium versus the S&P 500 average of 2.82 and a significant discount versus the industry average of 7.08. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average.
|BABY 41.30||Peers 34.06||BABY NA||Peers 26.57|
Premium. A higher P/E ratio than its peers can signify a more expensive stock or higher growth expectations.
BABY is trading at a premium to its peers.
Neutral. The P/CF ratio is the stock’s price divided by the sum of the company's cash flow from operations. It is useful for comparing companies with different capital requirements or financing structures.
Ratio not available.
|BABY 27.21||Peers 25.19||BABY 0.83||Peers 0.96|
Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.
BABY is trading at a premium to its peers.
Discount. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
BABY trades at a discount to its peers.
|BABY 4.07||Peers 7.08||BABY 20.43||Peers 9.77|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
BABY is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
BABY is expected to have an earnings growth rate that significantly exceeds its peers.
|BABY 4.17||Peers 6.01||BABY 4.95||Peers 11.17|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
BABY is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
BABY significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV